Acadian Asset Management LLC boosted its stake in shares of Agile Therapeutics Inc (NASDAQ:AGRX) by 33.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 417,269 shares of the specialty pharmaceutical company’s stock after purchasing an additional 104,222 shares during the quarter. Acadian Asset Management LLC’s holdings in Agile Therapeutics were worth $630,000 as of its most recent filing with the SEC.
Separately, BlackRock Inc. grew its position in shares of Agile Therapeutics by 15.7% during the 4th quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after acquiring an additional 18,038 shares during the period. 42.38% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have recently commented on the company. Maxim Group set a $3.00 target price on Agile Therapeutics and gave the company a “buy” rating in a research report on Monday. Oppenheimer assumed coverage on Agile Therapeutics in a research report on Thursday, June 6th. They set an “outperform” rating and a $5.00 target price on the stock. ValuEngine upgraded Agile Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Finally, Janney Montgomery Scott assumed coverage on Agile Therapeutics in a research report on Friday, April 12th. They set a “buy” rating and a $4.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $4.00.
In related news, CEO Alfred Altomari purchased 25,000 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were purchased at an average cost of $1.54 per share, with a total value of $38,500.00. Following the purchase, the chief executive officer now owns 238,568 shares of the company’s stock, valued at approximately $367,394.72. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Abhijeet J. Lele purchased 20,000 shares of the firm’s stock in a transaction that occurred on Friday, March 29th. The stock was bought at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the purchase, the director now directly owns 37,949 shares in the company, valued at approximately $58,441.46. The disclosure for this purchase can be found here. Insiders purchased a total of 65,000 shares of company stock worth $94,700 over the last ninety days. 8.50% of the stock is currently owned by corporate insiders.
NASDAQ:AGRX opened at $1.33 on Wednesday. Agile Therapeutics Inc has a 52 week low of $0.23 and a 52 week high of $1.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.91 and a current ratio of 8.91. The stock has a market cap of $56.86 million, a PE ratio of -2.29 and a beta of 0.64.
Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.02). As a group, analysts expect that Agile Therapeutics Inc will post -0.43 EPS for the current fiscal year.
WARNING: “Acadian Asset Management LLC Has $630,000 Holdings in Agile Therapeutics Inc (NASDAQ:AGRX)” was first published by Equities Focus and is the property of of Equities Focus. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.equitiesfocus.com/2019/06/12/acadian-asset-management-llc-has-630000-holdings-in-agile-therapeutics-inc-nasdaqagrx.html.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.
Recommended Story: What is a back-end load?
Want to see what other hedge funds are holding AGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agile Therapeutics Inc (NASDAQ:AGRX).
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.